Yan Leyfman, Medical Correspondent at OncLive, Freelance, shared on X:
“What determines whether an allogeneic CAR-T product succeeds – or gets rejected?
Allogeneic CAR-T therapy offers an attractive possibility: an ‘off-the-shelf‘ cellular therapy that could overcome many of the logistical limitations of autologous CAR-T.
But one major obstacle remains: immune rejection by the recipient.
A new study of 11 patients with large B-cell lymphoma treated with the same lot of cemacabtagene ansegedleucel (cema-cel) provides an important look at why outcomes can differ despite receiving essentially the same CAR-T product.
Using longitudinal TCRβ sequencing, single-cell molecular profiling, and mixed lymphocyte reaction assays, investigators identified two distinct mechanisms:
- Cell-extrinsic: Patients who failed to achieve CAR-T expansion had higher frequencies of pre-existing, recipient-derived alloreactive CD8⁺ T cells, which appeared to rapidly eliminate the infused CAR-T cells.
- Cell-intrinsic: Among patients whose CAR-T cells expanded, effector-like programs—not stem/central memory phenotypes – were associated with robust clonal expansion.
Importantly, similar expansion patterns were observed in independent cohorts receiving a separate cema-cel lot and an allogeneic anti-BCMA CAR-T product.
The bigger implication is that allogeneic CAR-T performance may depend on two sides of the equation: Can the product expand? And can the patient’s immune system tolerate it?
This moves allogeneic CAR-T development beyond simply engineering a potent CAR-T cell.
Future optimization may require simultaneously addressing recipient immune selection, donor selection, manufacturing, and the cellular state of the final product.
For ‘off-the-shelf‘ CAR-T to become truly interchangeable, we may ultimately need to understand and control the biology of the recipient – product interaction.”
Title: Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion
Authors: Andrew P. Jallouk, Zhongqi Ge, Vivek Kaimal, Kristen Zhang, Elvin J. Lauron, Paul B. Robbins, Zachary J. Roberts, Emerie Danson, Matthew D. Richard, Pragya Devashish, Sattva S. Neelapu
Other articles about CAR-T therapy on OncoDaily.